Indegene Limited · NSE:INDGN
Indegene — Q4 FY2025 Earnings Presentation
22 slides from Indegene's earnings presentation, Apr 28, 2025
Slide 1: Exchange filing cover letter
INDGN/SE/2025-26/09 April 28, 2025 BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai- 400001, India. Mumbai – 400 051, India. Scrip Code: 544172 Trading symbol: INDGN Dear Sir / Madam,
Slide 2: Investor Presentation April 2025
Investor Presentation TM April 2025
Slide 3: Disclaimer
Disclaimer This presentation may include opinions and assumptions about future performance which could be considered as forward-looking statements. Forward-looking statements intrinsically cover several risks and uncertainties, which may lead to a material difference between actual results and the s
Slide 4: We operate at the intersection of healthcare and technology
We operate at the intersection of healthcare and technology Healthcare Tech-Led Expertise Delivery and Healthcare market Digital understanding Capabilities Digital-first approach In-depth domain Gen AI based tools and platform knowledge Navigating regulatory landscape Drive transformation Medical co
Slide 5: We are a Digital First Commercialization Partner
We are a Digital First Commercialization Partner We Provide Capabilities and Expertise Across the Commercialization Value Chain Regulatory and R&D / Clinical Marketing and Sales Pharmacovigilance Medical Affairs and Others Brand Strategy and Pharmacovigilance Digital content Medical content Patient
Slide 6: Our large addressable market is underpinned by growing outsourcing and rapid digital adoption
Our large addressable market is underpinned by growing outsourcing and rapid digital adoption Large Market Opportunity Outsourcing and Tech Lifesciences at Inflection We Offer Solutions Expanding our TAM Point Across Life Sciences Life Sciences Operations Spend Across End Markets Verticals ($B) Pate
Slide 7: Management Commentary on Q4FY25 results
Management Commentary on Q4FY25 results Manish Gupta Suhas Prabhu Chairman and Chief Executive Officer Chief Financial Officer “We sustained our profitable growth momentum in Q4FY25, clocking “Q4FY25 rounded out another year of stable and profitable growth. We revenue growth of 4.9% QoQ, buoyed by r
Slide 8: Q4 FY25: Financial Highlights
Q4 FY25: Financial Highlights Significant INR 7,556 Mn 12.3% 7.8% growth at scale Revenue from Operations YoY revenue growth YoY revenue growth in INR terms in USD terms 20.2% 15.6% Strong EBITDA Margin PAT Margin margin profile 0.6% QoQ 0.3% QoQ © 2025 Indegene. All rights reserved. 7
Slide 9: FY25: Financial Highlights
FY25: Financial Highlights Significant INR 28,393 Mn 9.6% 7.3% growth at scale Revenue from Operations YoY revenue growth YoY revenue growth in INR terms in USD terms 19.8% 14.3% Strong EBITDA Margin PAT Margin margin profile 0.9% YoY 1.3% YoY © 2025 Indegene. All rights reserved. 8
Slide 10: FY25: Business Highlights
FY25: Business Highlights Strong client 73 41 66% relationships Active Client Relationships Clients with $1 Million+ Revenue from Top 20 Global Revenue Biopharma Companies Global 4,961/4,268 23.8% 16.6% Delivery Total Employees / Delivery Employees Delivery Headcount with Voluntary Attrition Healthc
Slide 11: Q4 FY25: Business mix
Q4 FY25: Business mix Revenue from Service offering ($Mn) Revenue by Customer Industry (%) Revenue by Customer Geography (%) 1.0% 81.1 85.2 87.4 2.6% 2.3% 4.8% 3.6% 3.0% 13.1% 12.4% 12.8% 2.6% 24.6% 71.9% 0.9% 58.3% 55.6% 56.3% 28.5% 27.9% 94.0% 23.8% Q4FY24 Q3FY25 Q4FY25 Q4FY25 Q4FY25 Enterprise Me
Slide 12: Q4 FY25: Segment Performance Update
Q4 FY25: Segment Performance Update Amount in INR Mn Segment performance QoQ Segment performance YoY 4,003 4,225 15,287 15,871 2,052 2,107 8,025 6,008 1,410 1,020 889 967 260 227 3,191 3,477 ECS EMS OMNICHANNEL OTHERS ECS EMS OMNICHANNEL OTHERS Q3 FY25 Q4 FY25 FY24 FY25 • Core segments (ECS & EMS) g
Slide 13: Growth Approach 1: Deeper Engagement with Large Pharma Customers
Growth Approach 1: Deeper Engagement with Large Pharma Customers Amount in INR Mn Revenue from Top 5 customers Revenue from Top 20 customers 11,345 11,984 11,347 21,657 22,082 19,321 9,176 14,320 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 • Growing Top 20 customers despite negative impacts in two of To
Slide 14: Growth Approach 2: Broader targeting leading to a wider, taller pyramid
Growth Approach 2: Broader targeting leading to a wider, taller pyramid 73 10 6 Active clients(1) Active clients (1) Incremental clients successfully grown to added in FY25 $1mn+ category in FY25 Growing active client base(1) Successful track record of growing accounts 41 35 34 2 28 3 8 4 4 6 3 73 2
Slide 15: Financial Highlights
Financial Highlights © 2025 Indegene. All rights reserved. 14
Slide 16: Q4 FY25 Consolidated Financials
Q4 FY25 Consolidated Financials Amount in INR Mn Particulars Q4 FY25 Q3 FY25 Q4 FY24 QoQ % YoY% FY25 FY24 YoY% Revenue from Operations 7,556 7,204 6,730 4.9% 12.3% 28,393 25,896 9.6% Employee Benefit Expenses 4,851 4,438 4,284 9.3% 13.2% 18,152 16,516 9.9% Other Expenses 1,230 1,448 1,059 -15.1% 16.
Slide 17: Healthy margin profile and robust balance sheet
Healthy margin profile and robust balance sheet EBITDA and EBITDA Margin PAT and PAT Margin Cash and Cash Equivalent(1) INR Mn and % INR Mn and % INR Mn 15.6% 21.9% 20.8% 20.2% 15.2% 14.1% 1,176 16,643 1,474 1,501 1,526 1,097 15,079 948 9,876 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q
Slide 18: Investor Day - 24th March
Investor Day - 24th March • Hosted 75+ top analysts from buy-side and sell-side, including renowned firms like JP Morgan, Citi, Kotak, Premji Invest, among others • Showcased our business and technology portfolio via immersive demos, including the launch of Cortex, our GenAI platform contextualized
Slide 19: Awards and Recognitions
Awards and Recognitions © 2025 Indegene. All rights reserved. 18
Slide 20: Thank You!
Thank You! www.indegene.com
Slide 21: Fact Sheet: Operational & Financial Metrics
Fact Sheet Consolidated Financial Data - Fourth Quarter, Fiscal 2025 Operational & Financial Metrics Key performance indicators (in INR Mn) Quarter ended Growth Year ended SI. Particulars Mar 31, Dec 31, Mar 31, March 31, March 31, No. YoY QoQ 2025 2024 2024 2025 2024 1. Active clients(1)(No.) 73 75
Slide 22: Fact Sheet: Revenue by customer industry and client data
Fact Sheet Consolidated Financial Data - Fourth Quarter, Fiscal 2025 Revenue by customer industry (in %) Quarter ended (contribution) Growth Particulars Mar 31, Dec 31, Mar 31, YoY QoQ 2025 2024 2024 Biopharma 94.0 93.7 93.8 12.5 5.2 Medical Devices 2.6 2.6 2.8 4.1 5.2 Emerging Biotech 2.3 2.5 2.7 -